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November 2013 issue of Osteoarthritis and Cartilage1, have recently
been published highlighting the evolving ‘bench to bedside’
research on Regenerative Injection Therapies (RIT) for Osteoar-
thritis (OA). The impact of this globally debilitating pandemic is
well documented.
Under the correct circumstances, the joint appears to have the
ability to transiently and partially repair the extracellular matrix2,
but efforts to develop synthetic disease modifying drugs for OA
similar to the DMARD’s used in rheumatologic arthritides has
been unsuccessful thus far. There is currently no “cure” and deﬁn-
itive treatment remains total joint arthroplasty, which has its own
limitations and shortcomings3,4. Thus, interest has incrementally
developed in “Orthobiologics” to ﬁll this crucial void by attempting
to enhance innate capabilities. The Platelet Rich Plasma (PRP) mar-
ket, valued at $45million in 2009, is expected to triple over the next
few years, an upsurge primarily driven by sports medicine5.
What does or does not constitute a RIT is somewhat ambigu-
ously deﬁned but is generally characterized as having the ability
to mitigate pain and promote tissue repair and regeneration6. Ex-
amples of injectates most commonly implicated as having RIT-
type properties include Mesenchymal Stem Cells (MSC), Platelet
Concentrate (PC), Autologous Conditioned Serum (ACS), and
Dextrose Prolotherapy. MSC, PC, and ACS are all biologics. The
term PC can be used as an umbrella term to encompass all platelet
concentrated autologous biologics, such as pure PRP, leukocyte PRP,
Platelet Rich Fibrin and Platelet Rich in Growth Factors and a num-
ber of other variations being developed. This progressing
complexity is exempliﬁed by new classiﬁcation systems continuallybeing proposed to keep pace with the development of new formu-
lation variants5,7,8.
Regardless of the intricacies of the respective formulation, most
current PC’s have their foundation in the rationale that creating an
injectate preparation with platelets concentrated at 2 or more
above that of the systemic circulation is advantageous for healing
and regeneration of tissues because of the growth factors contained
within platelet granules, synergistic effects with MSCs, anti-
inﬂammatory properties, etc1.
The total number of human clinical studies involving the percu-
taneous, intraarticular (IA) utilization of PC for osteocartilaginous
disease is approaching twenty9e13 and several randomized
controlled trials have been completed9. Although all have their in-
sufﬁciencies and there is signiﬁcant heterogeneity, they have
shown predominantly positive subjective outcomes with favorable
safety proﬁles. With a few exceptions14, these results correlate
congruently with most in vitro human and in vivo and in vitro ani-
mal studies1.
However, the news for PC is not all positive. Several of these clin-
ical studies demonstrate reduction in efﬁcacy over time9,10, suggest-
ing an inability of current formulations to consistently maintain a
sustained effect. Also, there seems to be subgroups of individuals
with OA (e.g., elderly with advanced diseased), who experience
equivalent improvement after one or more injections of PC. Lastly,
since the ﬁrst tenet of medicine is non-maleﬁcence, factors con-
tained within PC preparations in varying concentrations that are
postulated to be deleterious, (e.g., VEGF in PC, MMP’s in leukocytes
and iron in erythrocytes) have created some apprehension1,12,15.
Supported by the heterogeneity of preparations utilized, there is
a great deal of confusion regarding which preparation(s) are most
effective and if this differs depending on the patient, disease loca-
tion and severity12,15,16. Clinical studies up to the present have pri-
marily focused on whether or not PC is clinically efﬁcacious in
reducing pain and improving quality of life. There is foundational
in vitro biological mechanism of action (BMoA) data17 and recently
very limited animal in vivo BMoA data has been collected, but the
elucidation of the in vivo human BMoA has not yet commenced18,19.
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robust. Human imaging data is sparse, but case reports and anec-
dotal experiences are continually surfacing1,11. Indeed, there is a
scarcity of correlative evidence in humans that PC is able to stimu-
late a chondroinductive regenerative effect on the biochemical
microenvironment of the joint milieu to aid in the repair of histo-
morphologically diseased, inﬂamed structures within the joint.
Based on the paucity of data available, there is skepticism about
whether IA PC in the treatment of human OA is a RIT per se15. For
example, the primary BMoA could be anti-inﬂammatory effects
on either nociceptive and/or neurogenic inﬂammation and/or a pla-
cebo effect based on patient expectations of a new and innovative
biological treatment9.
We feel that this provokes two important questions. Would it be
beneﬁcial to know: (1) if IA PC is able reliably stimulate regenera-
tion of diseased tissue and/or stabilize degradation and/or mitigate
bonemarrow lesions and synovitis and (2) what is occurring within
the joint on a cellular and molecular level after IA PC leading to any
observed structural changes and the aforementioned improvement
in clinical outcomes measures.
The routine implementation of baseline and post injection com-
parison magnetic resonance imaging (addressing #1 above) in and
of itself would be valuable. The reasons for this are fairly obvious as
is the limitations of plain radiographs and thus will not be bela-
bored here. The beneﬁts of incorporating biochemical and cellular
outcome data (addressing #2 above) in a similar fashion as the ﬁnal
piece to an “outcome triad”, may not be as evident and several ex-
amples are provided below.
 Elucidation of the pharmacokinetics within the joint permitting
the subsequent determination of both the half-lives and optimal
“therapeutic window(s)”11 of growth factors.
 Determination of the true in vivo signiﬁcance of markers
implicated as being harmful and whether natural antagonistic
factors play a role in nullifying the counterproductive effects. For
example, VEGF is accompanied by an anti-angiogenic factor, PR-
4, within the platelet granules. Zhu et al. propose the idea of
adjunctively using antibodies directed toward destructive
markers. This could have tremendous beneﬁt, especially once
the interplays and effects are better understood1,14,20.
 Integration of this data with complementary efforts dedicated
toward revealing the extent of differing pathophysiological
pathways based on the underlying pathoetiology21,22 may assist
in clarifying whether or not personalized MSK medicine23 using
preparations based on an individuals biological uniqueness will
be beneﬁcial in minimizing the current enigma of unpredict-
ability of those who are ultimately labeled as non-responders.
*The merit of this data would be largely dependent on having
intraindividual clinical and advanced imaging outcome data.
Without these additional components, valid interpretation of the
biochemical and cellular data would be problematic and subject
to considerable conjecture.
There are numerous challenges of incorporating multiple
measurable end-points in a longitudinal study design such as:
limited ability to predict imaging progressors vs non-progressors
(randomization would be anticipated to lessen the likelihood of
this resulting in erroneous results); discordance of many imaging
markers to patient symptomatology; complexity of biochemical
markers and the associated signaling pathways, diurnal and activity
inﬂuenced deviations in marker concentrations, limited synovial
ﬂuid for analysis, and substantial added costs. These obstacles are
certainly formidable, but unlikely to be insurmountable in preclud-
ing accurate and meaningful data to be gathered.Using the longitudinal “outcome triad” of (1) molecular and
cellular responses within the IA space along with concurrent acquisi-
tion and correlation with (2) clinical and (3) imaging outcomes, all
in comparison to baseline, couldbe an integral step in scientiﬁcally
validating or disproving cell based biologics as RIT, understanding
the mechanisms involved and lead to more precipitous advancement
in effectiveness. Realizing the worth of biochemical and imaging
biomarkers in RIT studies is not a novel idea12,24, but we hope
this editorial will serve to highlight the potential valuableness of
this triad working in solidarity.
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